{"url_path":"/sec/cdio/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1870144/0001553350-26-000089-index.html","accession_number":"0001553350-26-000089","cik":"0001870144","ticker":"CDIO","issuer_name":"Cardio Diagnostics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1870144/0001553350-26-000089-index.html","primary_entity_key":"0001870144","primary_entity_name":"Cardio Diagnostics Holdings, Inc."},"word_count":580,"has_tables":true,"body_markdown":"**ITEM 6. EXHIBITS**\n\n \n\nThe following exhibits are filed as part of,\nor incorporated by reference into, this Quarterly Report on Form 10-Q.\n\n \n\n \n \n \n \n**Incorporation by Reference**\n\n**Exhibit Number**\n \n**Description**\n \n**Form**\n \n**Exhibit**\n \n \n**Filing\nDate**\n\n \n \n \n \n \n \n \n \n \n \n\n2.1\n \n[Agreement and Plan of Merger dated as of May 27, 2022 by and among Mana Capital Acquisition Corp., Mana Merger Sub, Inc., Cardio Diagnostics, Inc., and Meeshanthini (Meesha) Dogan, as representatives of the shareholders (included as Annex A to the Proxy Statement/Prospectus)](http://www.sec.gov/Archives/edgar/data/1870144/000107997322000718/ex2x1.htm)\n \n8-K\n \n \n2.1\n \n \n5/31/2022\n\n2.2\n \n[Amendment dated September 15, 2022 to Agreement and Plan of Merger dated as of May 27, 2022 by and among Mana Capital Acquisition Corp., Mana Merger Sub, Inc., Cardio Diagnostics, Inc., and Meeshanthini (Meesha) Dogan, as representatives of the shareholders](http://www.sec.gov/Archives/edgar/data/1870144/000107997322001116/ex2x1.htm)\n \n8-K\n \n \n2.1\n \n \n9/15/22\n\n2.3\n \n[Waiver Agreement dated as of October 25, 2022 with respect to Agreement and Plan of Merger dated as of May 27, 2022, as amended on September 15, 2022](http://www.sec.gov/Archives/edgar/data/1870144/000107997322001382/ex2x3.htm)\n \n8-K\n \n \n2.3\n \n \n10/31/22\n\n3.1\n \n[Third Amended and Restated Certificate of Incorporation of Cardio Diagnostics Holdings, Inc., dated May 30, 2023](http://www.sec.gov/Archives/edgar/data/1870144/000107997323000793/ex3x1.htm)\n \n8-K\n \n \n3.1\n \n \n5/30/23\n\n3.2\n \n[By-laws](http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex3x3.htm)\n \nS-1\n \n \n3.3\n \n \n10/19/21\n\n3.3\n \n[Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of Cardio Diagnostics Holdings, Inc. dated May 12, 2025](http://www.sec.gov/Archives/edgar/data/1870144/000107997325000781/ex3x1.htm)\n \n8-K\n \n \n3.1\n \n \n5/13/2025\n\n4.1\n \n[Specimen Stock Certificate](http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex4z2.htm)\n \nS-1/A\n \n \n4.2\n \n \n11/10/21\n\n4.2\n \n[Specimen Warrant Certificate (contained in Exhibit 4.3)](http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex4z1.htm)\n \n8-K\n \n \n4.1\n \n \n11/26/21\n\n4.3\n \n[Warrant Agreement, dated November 22, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent](http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex4z1.htm)\n \n8-K\n \n \n4.1\n \n \n11/26/21\n\n4.4\n \n[Description of Securities](http://www.sec.gov/Archives/edgar/data/1870144/000107997324000480/ex4x5.htm)\n \n10-K\n \n \n4.5\n \n \n4/1/24\n\n \n\n \n\n \n\n26 \n\n \n\n \n\n \n\n \n \n \n \n**Incorporation by Reference**\n\n**Exhibit Number**\n \n**Description**\n \n**Form**\n \n**Exhibit**\n \n \n**Filing\nDate**\n\n \n \n \n \n \n \n \n \n \n \n \n\n31.1*\n \n[Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31x1.htm)\n \n \n \n \n \n \n \n \n\n31.2*\n \n[Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31x2.htm)\n \n \n \n \n \n \n \n \n\n32.1+\n \n[Certification of Principal Executive Officer pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32x1.htm)\n \n \n \n \n \n \n \n \n\n32.2+\n \n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32x2.htm)\n \n \n \n \n \n \n \n \n\n101.INS*\n \nInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)\n\n101.SCH*\n \nXBRL Taxonomy Extension Schema Document.\n \n \n \n \n \n \n \n \n\n101.CAL*\n \nXBRL Taxonomy Extension Calculation Linkbase Document\n \n \n \n \n \n \n \n \n\n101.DEF*\n \nXBRL Taxonomy Extension Definition Linkbase Document\n \n \n \n \n \n \n \n \n\n101.LAB*\n \nXBRL Taxonomy Extension Label Linkbase Document\n \n \n \n \n \n \n \n \n\n101.PRE*\n \nXBRL Taxonomy Extension Presentation Linkbase Document\n \n \n \n \n \n \n \n \n\n104*\n \nCover Page Interactive Date File (embedded with the Inline XBRL document)\n\n \n \n \n \n \n \n \n \n \n \n \n\n  \n\n*   \nFiled herewith.\n \n\n+\n\nFurnished\nherewith. The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished\nand not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Cardio Diagnostics\nHoldings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or\nafter the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n \n\n \n\n \n\n \n\n  ** **\n\n27 \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto\nduly authorized.\n\n \n\n \n**Cardio Diagnostics Holdings, Inc.**\n\n \n \n \n\n Date: May 15, 2026\nBy:  \n/s/ Elisa Luqman\n\n \n \nElisa Luqman\n\n \n \nChief Financial Officer\n\n \n\n \n\n \n\n28"}